Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Colorectal Neoplasms 90Carcinoma, Hepatocellular 29Neoplasm Metastasis 18Neoplasms 16Gastrointestinal Stromal Tumors 13Colonic Neoplasms 13Rectal Neoplasms 12Sarcoma 6Glioblastoma 6Stomach Neoplasms 5Sarcoma, Ewing 5Ovarian Neoplasms 5Osteosarcoma 5Melanoma 5Liver Neoplasms 5Adenocarcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 3Rhabdomyosarcoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Leukemia, Myeloid, Acute 3Colorectal Cancer Metastatic 3Carcinoma, Transitional Cell 3Carcinoma 3Advanced Colorectal Cancer 3Thyroid Neoplasms 2

Interventions

Everolimus 5Octreotide 4Leucovorin 4Temozolomide 3Oxaliplatin 3Fluorouracil 3Capecitabine 3vatalanib 2temsirolimus 2Trastuzumab 2Sirolimus 2Melphalan 2Irinotecan 2Biological Therapy 2Bevacizumab 2tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1napabucasin 1motesanib diphosphate 1irinotecan sucrosofate 1folfirinox 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1Vinorelbine 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Islet Cell × regorafenib × Clear all
NCT02259725 2021-12-15

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

University of Southern California

Phase 2 Completed
3 enrolled 7 charts
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡